Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free BDMD Stock Alerts

Baird Medical Investment (BDMD) Competitors

Baird Medical Investment logo
$1.10 -0.02 (-1.79%)
Closing price 08/31/2026 04:00 PM Eastern
Extended Trading
$1.10 +0.00 (+0.45%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BDMD vs. CNXU, FOCL, OWLT, INGN, and KRMD

Should you buy Baird Medical Investment stock or one of its competitors? Baird Medical Investment's main competitors and comparable companies include Conexeu Sciences (CNXU), FocalTherics (FOCL), Owlet (OWLT), Inogen (INGN), and KORU Medical Systems (KRMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Baird Medical Investment compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Baird Medical Investment has higher revenue and earnings than Conexeu Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/A-$3.92M-$0.11N/A
Baird Medical Investment$22.54M2.06N/AN/AN/A

19.8% of Baird Medical Investment shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A N/A N/A
Baird Medical Investment N/A N/A N/A

In the previous week, Conexeu Sciences and Conexeu Sciences both had 1 articles in the media. Conexeu Sciences' average media sentiment score of 1.89 beat Baird Medical Investment's score of 1.87 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Conexeu Sciences Very Positive
Baird Medical Investment Very Positive

Conexeu Sciences presently has a consensus price target of $20.00, suggesting a potential upside of 178.55%. Given Conexeu Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Conexeu Sciences is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Conexeu Sciences beats Baird Medical Investment on 4 of the 7 factors compared between the two stocks.

How does Baird Medical Investment compare to FocalTherics?

Baird Medical Investment (NASDAQ:BDMD) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Baird Medical Investment has higher earnings, but lower revenue than FocalTherics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baird Medical Investment$22.54M2.06N/AN/AN/A
FocalTherics$70.53M2.27-$29.25M-$1.03N/A

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Baird Medical Investment has a beta of -1.16, meaning that its share price is 216% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

In the previous week, FocalTherics had 15 more articles in the media than Baird Medical Investment. MarketBeat recorded 16 mentions for FocalTherics and 1 mentions for Baird Medical Investment. Baird Medical Investment's average media sentiment score of 1.87 beat FocalTherics' score of 0.78 indicating that Baird Medical Investment is being referred to more favorably in the media.

Company Overall Sentiment
Baird Medical Investment Very Positive
FocalTherics Positive

Baird Medical Investment has a net margin of 0.00% compared to FocalTherics' net margin of -56.26%. Baird Medical Investment's return on equity of 0.00% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
Baird Medical InvestmentN/A N/A N/A
FocalTherics -56.26%-248.00%-44.69%

FocalTherics has a consensus price target of $7.75, suggesting a potential upside of 81.50%. Given FocalTherics' stronger consensus rating and higher probable upside, analysts plainly believe FocalTherics is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
FocalTherics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40

Summary

FocalTherics beats Baird Medical Investment on 9 of the 14 factors compared between the two stocks.

How does Baird Medical Investment compare to Owlet?

Owlet (NYSE:OWLT) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Owlet presently has a consensus target price of $15.00, indicating a potential upside of 202.42%. Given Owlet's stronger consensus rating and higher probable upside, equities analysts clearly believe Owlet is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Owlet
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Baird Medical Investment has lower revenue, but higher earnings than Owlet.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Owlet$105.70M1.37-$39.68M-$0.75N/A
Baird Medical Investment$22.54M2.06N/AN/AN/A

Owlet has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Baird Medical Investment has a beta of -1.16, meaning that its stock price is 216% less volatile than the broader market.

72.6% of Owlet shares are owned by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are owned by institutional investors. 36.2% of Owlet shares are owned by insiders. Comparatively, 78.9% of Baird Medical Investment shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Owlet and Owlet both had 1 articles in the media. Baird Medical Investment's average media sentiment score of 1.87 beat Owlet's score of 1.84 indicating that Baird Medical Investment is being referred to more favorably in the news media.

Company Overall Sentiment
Owlet Very Positive
Baird Medical Investment Very Positive

Baird Medical Investment has a net margin of 0.00% compared to Owlet's net margin of -8.61%. Baird Medical Investment's return on equity of 0.00% beat Owlet's return on equity.

Company Net Margins Return on Equity Return on Assets
Owlet-8.61% -601.24% -15.96%
Baird Medical Investment N/A N/A N/A

Summary

Owlet and Baird Medical Investment tied by winning 6 of the 12 factors compared between the two stocks.

How does Baird Medical Investment compare to Inogen?

Baird Medical Investment (NASDAQ:BDMD) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Inogen had 1 more articles in the media than Baird Medical Investment. MarketBeat recorded 2 mentions for Inogen and 1 mentions for Baird Medical Investment. Baird Medical Investment's average media sentiment score of 1.87 equaled Inogen'saverage media sentiment score.

Company Overall Sentiment
Baird Medical Investment Very Positive
Inogen Very Positive

Baird Medical Investment has higher earnings, but lower revenue than Inogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baird Medical Investment$22.54M2.06N/AN/AN/A
Inogen$348.67M0.41-$22.75M-$0.90N/A

Baird Medical Investment has a net margin of 0.00% compared to Inogen's net margin of -6.94%. Baird Medical Investment's return on equity of 0.00% beat Inogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Baird Medical InvestmentN/A N/A N/A
Inogen -6.94%-13.17%-8.36%

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Comparatively, 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Baird Medical Investment has a beta of -1.16, meaning that its share price is 216% less volatile than the broader market. Comparatively, Inogen has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Inogen
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Summary

Inogen beats Baird Medical Investment on 6 of the 11 factors compared between the two stocks.

How does Baird Medical Investment compare to KORU Medical Systems?

Baird Medical Investment (NASDAQ:BDMD) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Baird Medical Investment has a net margin of 0.00% compared to KORU Medical Systems' net margin of -4.03%. Baird Medical Investment's return on equity of 0.00% beat KORU Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Baird Medical InvestmentN/A N/A N/A
KORU Medical Systems -4.03%-10.63%-6.51%

Baird Medical Investment has a beta of -1.16, meaning that its share price is 216% less volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Baird Medical Investment has higher earnings, but lower revenue than KORU Medical Systems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baird Medical Investment$22.54M2.06N/AN/AN/A
KORU Medical Systems$41.13M3.69-$2.64M-$0.04N/A

KORU Medical Systems has a consensus price target of $7.00, suggesting a potential upside of 112.12%. Given KORU Medical Systems' stronger consensus rating and higher probable upside, analysts plainly believe KORU Medical Systems is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
KORU Medical Systems
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, KORU Medical Systems had 2 more articles in the media than Baird Medical Investment. MarketBeat recorded 3 mentions for KORU Medical Systems and 1 mentions for Baird Medical Investment. Baird Medical Investment's average media sentiment score of 1.87 beat KORU Medical Systems' score of 1.22 indicating that Baird Medical Investment is being referred to more favorably in the media.

Company Overall Sentiment
Baird Medical Investment Very Positive
KORU Medical Systems Positive

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by insiders. Comparatively, 18.5% of KORU Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

KORU Medical Systems beats Baird Medical Investment on 8 of the 13 factors compared between the two stocks.

Get Baird Medical Investment News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDMD vs. The Competition

Export
MetricBaird Medical InvestmentHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$47.27M$5.83B$7.20B$12.89B
Dividend YieldN/A1.75%2.54%11.27%
P/E RatioN/A25.97272.6125.48
Price / Sales2.0671.60626.6697.10
Price / CashN/A33.6928.7436.03
Price / BookN/A6.2411.056.34
Net IncomeN/A$149.14M$3.47B$349.45M
7 Day Performance-8.33%-0.61%0.25%-0.65%
1 Month Performance6.80%6.50%8.27%4.48%
1 Year Performance-55.10%5.87%24.14%14.89%

Baird Medical Investment Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDMD
Baird Medical Investment
1.3124 of 5 stars		$1.10
-1.8%		N/A-55.1%$47.27M$22.54MN/AN/A
CNXU
Conexeu Sciences
3.7234 of 5 stars		$7.00
-7.3%		$20.00
+185.7%		N/A$187.31MN/AN/A4
FOCL
FocalTherics
4.4485 of 5 stars		$4.40
+0.2%		$7.75
+76.1%		N/A$165.13M$70.53MN/A230
OWLT
Owlet
3.4022 of 5 stars		$5.14
-1.2%		$15.00
+191.8%		-34.0%$150.19M$105.70MN/A106
INGN
Inogen
1.2069 of 5 stars		$5.56
+0.4%		N/A-32.8%$147.56M$348.67MN/A1,030

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BDMD) was last updated on 9/1/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel